ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million, up from $17.4 million in the prior year, driven by higher volume and pricing. The company expects to announce topline results from the pivotal LOTIS-5 Phase 3 trial in the second quarter of 2026, with full data from both LOTIS-5 and LOTIS-7 anticipated by year-end.
Key figures
- Revenue
- $20.0 million
- Guidance
- LOTIS-5 topline data expected in 2Q 2026; cash runway at least into 2028
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.